CN116888140A - FimH突变体、其组合物及其用途 - Google Patents

FimH突变体、其组合物及其用途 Download PDF

Info

Publication number
CN116888140A
CN116888140A CN202280009667.0A CN202280009667A CN116888140A CN 116888140 A CN116888140 A CN 116888140A CN 202280009667 A CN202280009667 A CN 202280009667A CN 116888140 A CN116888140 A CN 116888140A
Authority
CN
China
Prior art keywords
fimh
polypeptide
mut
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280009667.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·格里杰普斯特拉
E·M·韦登堡
J·戈尔特森
K·C·法埃
L·J·费特斯马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CN116888140A publication Critical patent/CN116888140A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280009667.0A 2021-01-12 2022-01-11 FimH突变体、其组合物及其用途 Pending CN116888140A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12
EP21151126.6 2021-01-12
PCT/IB2022/050166 WO2022153166A1 (en) 2021-01-12 2022-01-11 Fimh mutants, compositions therewith and use thereof

Publications (1)

Publication Number Publication Date
CN116888140A true CN116888140A (zh) 2023-10-13

Family

ID=74175646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280009667.0A Pending CN116888140A (zh) 2021-01-12 2022-01-11 FimH突变体、其组合物及其用途

Country Status (12)

Country Link
US (3) US11725028B2 (https=)
EP (1) EP4277921A1 (https=)
JP (2) JP7532672B2 (https=)
KR (2) KR20250007029A (https=)
CN (1) CN116888140A (https=)
AR (1) AR124604A1 (https=)
AU (1) AU2022207740B2 (https=)
CA (1) CA3207841A1 (https=)
IL (1) IL303954B2 (https=)
MX (1) MX2023008251A (https=)
TW (1) TW202241929A (https=)
WO (1) WO2022153166A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
PE20241621A1 (es) * 2021-12-17 2024-08-07 Pfizer Composiciones de polinucleotidos y sus usos

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005978A1 (en) * 1999-07-15 2001-01-25 Medimmune, Inc. FimH ADHESIN-BASED VACCINES
US20020150587A1 (en) * 2000-07-07 2002-10-17 Solomon Langermann FimH adhesin proteins and methods of use
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US20030138449A1 (en) * 2000-08-18 2003-07-24 Medimmune, Inc. Method of administering FimH protein as a vaccine for urinary tract infections
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
WO2016183501A1 (en) * 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection
CN111094322A (zh) * 2017-09-08 2020-05-01 布里斯托大学 蛋白质的向膜递送

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
EP1874342B1 (en) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
US20190275134A1 (en) * 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US20240027467A1 (en) * 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005978A1 (en) * 1999-07-15 2001-01-25 Medimmune, Inc. FimH ADHESIN-BASED VACCINES
US20020150587A1 (en) * 2000-07-07 2002-10-17 Solomon Langermann FimH adhesin proteins and methods of use
US20030138449A1 (en) * 2000-08-18 2003-07-24 Medimmune, Inc. Method of administering FimH protein as a vaccine for urinary tract infections
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
WO2016183501A1 (en) * 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection
CN111094322A (zh) * 2017-09-08 2020-05-01 布里斯托大学 蛋白质的向膜递送

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GHOSH ARUNITA等: "Incidence of multidrug resistance, pathogenicity island markers, and pathoadaptive FimH mutations in uropathogenic Escherichia coli isolated from asymptomatic hospitalized patients.", FOLIA MICROBIOLOGICA, SPRINGER NETHERLANDS, vol. 64, no. 5, pages 587 - 600 *
PEARL MAGALA等: "RMSD analysis of structures of the bacterial protein FimH identifies five conformations of its lectin domain.", PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 88, no. 4, pages 593 - 603, XP055706802, DOI: 10.1002/prot.25840 *
VICTORIA B.RODRIGUEZ等: "Allosteric coupling in the bacterial adhesive protein FimH.", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 288, no. 33, pages 24128 - 24139, XP055518052, DOI: 10.1074/jbc.M113.461376 *

Also Published As

Publication number Publication date
US11725028B2 (en) 2023-08-15
MX2023008251A (es) 2023-07-26
JP7532672B2 (ja) 2024-08-13
TW202241929A (zh) 2022-11-01
US20220220159A1 (en) 2022-07-14
JP2024109576A (ja) 2024-08-14
IL303954B1 (en) 2024-12-01
AR124604A1 (es) 2023-04-12
AU2022207740B2 (en) 2024-06-06
US20230406890A1 (en) 2023-12-21
US12297238B2 (en) 2025-05-13
KR20250007029A (ko) 2025-01-13
IL303954A (en) 2023-08-01
IL303954B2 (en) 2025-04-01
JP2024502854A (ja) 2024-01-23
CA3207841A1 (en) 2022-07-21
KR102746713B1 (ko) 2024-12-24
KR20230125842A (ko) 2023-08-29
US20250289854A1 (en) 2025-09-18
AU2022207740A1 (en) 2023-06-29
AU2022207740A9 (en) 2024-09-05
EP4277921A1 (en) 2023-11-22
WO2022153166A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
US12428449B2 (en) FimH mutant, compositions therewith and use thereof
US12297238B2 (en) FimH mutants, compositions therewith and use thereof
EA050404B1 (ru) Мутанты fimh, композиции с ними и их применение
HK40118175A (en) Fimh mutant, compositions therewith and use thereof
EA047213B1 (ru) Мутантная форма fimh, композиции на ее основе и их применение
HK40084704B (en) Fimh mutant, compositions therewith and use thereof
HK40084704A (en) Fimh mutant, compositions therewith and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20260421